EVC2 抗体 (AA 30-199)
Quick Overview for EVC2 抗体 (AA 30-199) (ABIN7158397)
抗原
See all EVC2 抗体适用
宿主
克隆类型
标记
应用范围
- 
    - 
                                            抗原表位
- AA 30-199
- 
                                            交叉反应
- 人
- 
                                            纯化方法
- >95%, Protein G purified
- 
                                            免疫原
- Recombinant Human Limbin protein (30-199AA)
- 
                                            亚型
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            应用备注
- Recommended dilution: IHC:1:200-1:500, IF:1:50-1:200,
- 
                                            限制
- 仅限研究用
 
- 
                                            
- 
    - 
                                            状态
- Liquid
- 
                                            缓冲液
- 
                        Preservative: 0.03 % Proclin 300
 Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4
- 
                                            储存液
- ProClin
- 
                                            注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 
                                            储存条件
- -20 °C,-80 °C
- 
                                            储存方法
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
 
- 
                                            
- 
    - EVC2 (Ellis Van Creveld Syndrome 2 (EVC2))
- 
                                            别名
- EVC2
- 
                                            背景
- 
                        Background: Positive regulator of the hedgehog signaling pathway (By similarity). Plays a critical role in bone formation and skeletal development. Aliases: EVC2 antibody, LBN antibody, Limbin antibody, Ellis-van Creveld syndrome protein 2 antibody, EVC2 antibody 
- 
                                            UniProt
- Q86UK5
- 
                                            途径
- Hedgehog Signaling
 抗原
- 
                    
 
                                     
                                     
                                    